U.S. Markets open in 7 hrs 15 mins

iTeos Therapeutics, Inc. (ITOS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
24.32-0.82 (-3.26%)
At close: 4:00PM EDT

iTeos Therapeutics, Inc.

139 Main Street
Cambridge, MA 02142
United States
339 217 0161

Full Time Employees68

Key Executives

NameTitlePayExercisedYear Born
Dr. Michel DetheuxPres, CEO & Director833.75kN/A1966
Mr. Matthew GallChief Financial Officer628.45kN/A1977
Dr. Joanne Jenkins Lager M.D.Chief Medical Officer705.56kN/A1971
Mr. Matthew A. Call M.B.A.Chief Operating OfficerN/AN/A1973
Mr. Ryan BakerHead of Investor RelationsN/AN/AN/A
Mr. Philippe BrantegemVice-Pres of HRN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.